Studies from Medical University of Warsaw Reveal New Findings on Atrial Fibrillation (Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial)

摘要

2021 MAY 05 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily - Current study results on atrial fibrillation have been published. According to news originating from Warsaw, Poland, by NewsRx editors, the research stated, "We aimed to compare long-term outcomes in Polish patients with atrial fibrillation (AF) according to oral anticoagulation (OAC) type and to evaluate the predictive value of common thromboembolic and bleeding risk scores. Data from the CRAFT trial (NCT02987062) were included." The news journalists obtained a quote from the research from Medical University of Warsaw: "The primary study endpoint was major adverse event (MAE; all-cause death, thromboembolic and hemorrhagic event) during the mean four-year follow-up period. Out of 2983 patients with available follow-up data, 1686 (56%) were prescribed with vitamin K antagonist (VKA), 891 (30%) with rivaroxaban and 406 (14%) with dabigatran. Predominance of elderly and female patients with previous history of thromboembolic and hemorrhagic events was observed within rivaroxaban (vs. other OAC) group.